- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07641400
Pulmonary Artery Pressure in Predicting Pulmonary Embolism in Patients Presenting To The Emergency Department With Dyspnea
June 6, 2026 updated by: Antalya Health Sciences University
The Diagnostic Value of The Difference Between Prior and Immediate Pulmonary Artery Pressure in Predicting Pulmonary Embolism in Patients Presenting To The Emergency Department With Dyspnea
The aim of this study is to determine the usability of echocardiographic PAP changes obtained from emergency department records in the early risk stratification of pulmonary embolism.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Detailed Description
Pulmonary embolism (PE) is a significant clinical condition requiring rapid diagnosis, with high mortality and morbidity, in patients presenting to the emergency department with shortness of breath.
The chronic presence of dyspnea, particularly in individuals with chronic obstructive pulmonary disease (COPD), chronic heart failure, pulmonary hypertension, and similar cardiopulmonary diseases, makes it difficult to differentiate PE in the acute phase.
In this patient group, pulmonary artery pressure (PAP) values measured by echocardiography can provide important clinical information in the diagnostic process.
The aim of this study is to determine the usability of echocardiographic PAP changes obtained from emergency department records in the early risk stratification of pulmonary embolism.
Study Type
Observational
Enrollment (Estimated)
80
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: MURAT DUYAN, ASSOCIATE PROFESSOR
- Phone Number: +905404120735
- Email: drmuratduyan@gmail.com
Study Locations
-
-
-
Antalya, Turkey (Türkiye)
- University of Health Sciences, Antalya Training and Research Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients aged 18 and over who present to the emergency department with dyspnea between the specified study dates, are diagnosed with pulmonary embolism, have had their pulmonary artery pressure measured, have a previous pulmonary artery pressure measurement in their patient records, and have complete clinical, laboratory, imaging, and echocardiography data will be included in the study.
Description
Inclusion Criteria:
- Presenting to the emergency department with dyspnea between the specified dates,
- Being 18 years of age or older,
- Being evaluated in the emergency department with a preliminary diagnosis of pulmonary embolism,
- Having a recorded pulmonary artery pressure measurement at the time of hospital admission,
- Having a previous pulmonary artery pressure measurement in the patient's records,
- Having sufficient and complete clinical, laboratory, imaging, and echocardiography data available for the study.
Exclusion Criteria:
- Patients under 18 years of age,
- Lack of pulmonary artery pressure data from the time of emergency admission or from the previous period,
- Lack of necessary clinical, laboratory, or imaging data for pulmonary embolism evaluation,
- In cases of repeated admissions for the same patient, only the first suitable admission will be considered; other admissions will be excluded from the study,
- Patients whose data is unavailable in the record system or whose data is insufficient to be analyzed for research purposes.Inclusion Criteria for the Study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Pulmonary embolism (+)
|
patients diagnosed with pulmonary embolism who have previously had their pulmonary artery pressure measured
|
|
Pulmonary embolism (-)
|
control group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
pulmonary artery pressure
Time Frame: 3 hours
|
The difference between the pulmonary artery pressure measured in the previous echocardiogram and the pulmonary artery pressure at the time of admission to the emergency department.
|
3 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the relationship between pulmonary embolism and comorbidity
Time Frame: 3 hours
|
The relationship between the degree of increase in pulmonary artery pressure and pulmonary embolism in patients with COPD and heart failure.
|
3 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: MURAT DUYAN, ASSOCIATE PROFESSOR, University of Health Sciences, Antalya Training and Research Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2026
Primary Completion (Estimated)
September 1, 2026
Study Completion (Estimated)
October 1, 2026
Study Registration Dates
First Submitted
June 1, 2026
First Submitted That Met QC Criteria
June 6, 2026
First Posted (Actual)
June 11, 2026
Study Record Updates
Last Update Posted (Actual)
June 11, 2026
Last Update Submitted That Met QC Criteria
June 6, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 9/28
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Hypertension
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
VIVUS LLCNot yet recruitingPulmonary Arterial Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension WHO Group I | Pulmonary Arterial Hypertension PAH
-
Rutgers, The State University of New JerseyRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension of Congenital Heart Disease | Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder) | Pulmonary Arterial and Chronic Thromboembolic... and other conditionsUnited States
-
Poitiers University HospitalNot yet recruitingChronic Thromboembolic Pulmonary Hypertension (CTEPH) | Pulmonary Arterial Hypertension (PAH)
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Inhibikase TherapeuticsNot yet recruitingPulmonary Arterial Hypertension (PAH)
-
Guangdong Provincial People's HospitalRecruitingIdiopathic Pulmonary HypertensionChina
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyNot yet recruiting
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of MichiganNot yet recruitingPulmonary Arterial Hypertension (PAH)United States
-
University of Sao Paulo General HospitalRecruitingPulmonary Arterial Hypertension (PAH)Brazil
Clinical Trials on Pulmonary embolism (+)
-
University Hospital, Basel, SwitzerlandCompletedMissed Pulmonary Embolism at the Emergency Department
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Intermountain Health Care, Inc.Completed
-
Mark W. DodsonUnknownChronic Thromboembolic Pulmonary HypertensionUnited States
-
University Hospital, Strasbourg, FranceTerminatedPulmonary EmbolismFrance
-
University Hospital, GrenobleSanofi; Ministry of Health, France; SFMV (Société Française de Médecine Vasculaire)CompletedVascular Diseases | Embolism and Thrombosis | Venous Insufficiency | Phlebitis | Pulmonary EmbolismFrance, Belgium, Guadeloupe
-
Società Italiana di Medicina di Emergenza-UrgenzaCompletedPulmonary Embolism | HemoptysisItaly
-
University of CalgaryCompletedPulmonary Embolism | Clinical Reasoning | Diagnostic Uncertainty | Evidence Based Medicine | Visualization of UncertaintyCanada
-
Aysel SünnetçioğluYuzuncu Yıl UniversityCompleted